Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...
Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer ...
New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical ...
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with ...
Early-stage studies presented at ESMO reported promising activity for several experimental treatments for advanced prostate cancer. Johnson & Johnson’s oral JNJ-6143 produced substantial PSA declines ...
Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 3.5 million men in the United States who have been diagnosed with prostate ...
Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An ...
STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMOSOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ...
A crowd of South African men ran through the streets of Johannesburg in purple swim briefs to raise awareness about prostate ...
Daily Mail on MSN
Scientists discover a way to spot men at risk of prostate cancer more than a DECADE before symptoms
In the largest study of its kind, Oxford University researchers uncovered 12 proteins linked to the cancer after testing ...
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results